Sex: M
Vaccine: PNC13, PPV
Symptoms: Drug ineffective, Pneumonia, Respiratory tract infection
Clinical narrative: re-current pneumonia; re-current pneumonia; respiratory infections; This is a spontaneous report received from a Consumer or other non HCP from medical information team.  An 8-year-old male patient received pneumococcal 13-val conj vac (dipht CRM197 protein) (PREVNAR 13), as dose number unknown, single (Batch/Lot number: unknown) for immunisation; pneumococcal vaccine polysacch 23v (PNEUMOVAX 23), as dose number unknown, single) for immunisation. The patient's relevant medical history included: "stem cell transplant" (unspecified if ongoing), notes: stem cell transplant for a blood condition several years ago. The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), PNEUMONIA (medically significant), outcome "unknown" and all described as "re-current pneumonia"; RESPIRATORY TRACT INFECTION (non-serious), outcome "unknown", described as "respiratory infections".  Clinical course: A mother called about her eight-year-old son who had a stem cell transplant for a blood condition several years ago. He received about 20 vaccines, including Prevnar 13 and Pneumovax 23, due to chemotherapy. The caller read that it was recommended to wait about five years before giving another Prevnar 20 vaccine, but the doctor was about to administer it without consent. The caller is concerned that it may be too early for the vaccine and wants more information about the recommended interval. The son has had chronic illnesses, including re-current pneumonia and respiratory infections. Patient did not receive Prevnar 20.In adults, receipt of PPSV23 1 to 5 years prior to Prevnar 20 resulted in diminished OPA geometric mean titers (GMTs) to Prevnar 20 compared to OPA GMTs in recipients who received Prevnar 13 at least 6 months prior to Prevnar 20, and compared to OPA GMTs in recipients who received Prevnar 13 followed by PPSV23, with the last dose of PPSV23 given at least 1 year prior to Prevnar 20 [see Clinical Studies. The caller also wanted information about the effectiveness of Prevnar 20 in individuals under 18 years of age. Requested clarity on the statement below found in P.I. The effectiveness of Prevnar 20 for the prevention of pneumonia has not been established in individuals younger than 18 years of age. Pneumonia, on the other hand, is a broader term that refers to the infection or inflammation of the lung tissue by various pathogens such as bacteria (including S. pneumoniae), viruses, fungi, or parasites. In summary, S. pneumonia is a specific bacterium that is one of the common causes of pneumonia. Pneumonia, on the other hand, is a more general term that encompasses various types of lung infections caused by different pathogens. The effectiveness of Prevnar 20 for the prevention of invasive disease caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F has been established in individuals 6 weeks through 17 years of age.  The information on the batch/lot number for pneumococcal 13-val conj vac (dipht CRM197 protein), pneumococcal 13-val conj vac (dipht CRM197 protein) will be requested and submitted if and when received.